Overview

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Evaluate anti-cancer activity (e.g. proportion of patients with confirmed complete response or partial response) in patients with advanced, inoperable biopsy-proven hepatocellular carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Niacinamide
Sorafenib